BCD 700Alternative Names: BCD-700
Latest Information Update: 16 Dec 2016
At a glance
- Originator BIOCND
- Class Osteoporosis therapies
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Osteoporosis
Most Recent Events
- 16 Dec 2016 BIOCND plans to license BCD 700 (BIOCND pipeline, December 2016)
- 16 Dec 2016 Early research in Osteoporosis in South Korea (unspecified route)